Truist Securities strengthens its biotech equity research coverage

"Biotech continues to experience rapid evolution with new treatments and technologies, backed by compelling trial data, growing the market," said Mary Stroth, head of equity sales, trading, and research for Truist Securities. "Danielle's unique insights and analysis will complement our existing team as we advise our institutional clients to navigate factors that impact their investment strategies such as product innovation, loss of exclusivity, and new adjacency use cases." Brill's coverage will complement ...